Skip to content
  1. EMEA Innovative Medicine /
  2. Ibrutinib (IMBRUVICA®) Significantly Improved Progression-Free and Overall Survival Versus Chlorambucil in Treatment-Naïve Patients with Chronic Lymphocytic Leukaemia

Ibrutinib (IMBRUVICA®) Significantly Improved Progression-Free and Overall Survival Versus Chlorambucil in Treatment-Naïve Patients with Chronic Lymphocytic Leukaemia

Ibrutinib (IMBRUVICA®) Significantly Improved Progression-Free and Overall Survival Versus Chlorambucil in Treatment-Naïve Patients with Chronic Lymphocytic Leukaemia